top of page

Taiwan company poised to disrupt global CGM market

Bionime Corporation announced that its continuous glucose meter (CGM) has been approved by Taiwan's Ministry of Health and Welfare for marketing,
Bionime CGM system; Photo creit: Bionime

The surging prevalence of diabetes, coupled with increased healthcare expenditure, technological advancements, and notable product launches by industry leaders, has propelled the global Continuous Glucose Monitoring (CGM) market to an anticipated value of $17 billion by 2028. This growth is supported by a robust compound annual growth rate of 19.16%, as reported by estimates from Knowledge Sourcing Intelligence.

Continuous glucose monitoring entails the use of a device to automatically estimate blood glucose levels throughout the day and night. Unlike conventional methods, CGM provides real-time information, enabling users to make informed decisions about their diet, physical activity, and medication.

In a groundbreaking move, Bionime Corporation, a trailblazing Taiwanese medical technology innovator, has received approval from Taiwan's Ministry of Health and Welfare to market its revolutionary continuous glucose meter (CGM). This regulatory approval propels Bionime into the global CGM arena, positioning it as a challenger to established industry giants. Notably, Bionime's CGM stands as the first device in Taiwan to secure clearance from the Taiwan Food and Drug Administration (TFDA).

With aspirations to forge a robust global presence, Bionime is leveraging its TFDA-approved CGM technology. In a market predominantly dominated by major players like Abbott, Dexcom, and Medtronic, Bionime has strategically positioned itself as a formidable contender. The company underscores its competitiveness on the global stage, citing a comprehensive analysis by eight world-renowned patent firms, which confirmed that its CGM received the Freedom To Operate (FTO) analysis report without any patent infringement. This positions Bionime's CGM as highly competitive and poised for success in the global market.

How does CGM system work

A CGM typically consists of three components: a tiny sensor inserted under the skin, a transmitter that sends information wirelessly, and a software program for data storage and analysis.

The CGM device offers a painless alternative to traditional finger-stick testing, utilizing a small patch attached to the body for continuous glucose monitoring. Unlike conventional methods that require multiple daily tests, CGM provides users with real-time glucose data, offering accurate and non-intrusive monitoring for several days. Additionally, the CGM is usually waterproof, enhancing its usability and convenience.

Several prominent companies offer CGM systems with unique features:

  • Implantable sensor for long-term wear.

  • Smart transmitter with Bluetooth connectivity.

  • Lasts up to 6 months, eliminating frequent sensor insertions.

  • Removable smart transmitter.

  • Water-resistant, submerged for up to 30 minutes.

  • Continuous glucose monitoring for both type 1 and type 2 diabetes.

  • Predicts high or low glucose levels up to an hour in advance.

  • Easy-to-use app with automated data-sharing.

  • Sensor checks glucose levels every 5 minutes.

  • No fingersticks are required for real-time glucose numbers.

  • Proven results in lowering A1C levels.

  • Dexcom Clarity app for tracking glucose trends.


bottom of page